Capricor Therapeutics, Inc. financial data

Symbol
CAPR on Nasdaq
Industry
Pharmaceutical Preparations
Location
8840 Wilshire Blvd, 2 Nd Floor, Beverly Hills, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Nile Therapeutics, Inc. (to 11/20/2013), SMI PRODUCTS INC (to 9/19/2007)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 135 % -8.62%
Debt-to-equity 262 % -43.6%
Return On Equity -220 % +31.9%
Return On Assets -60.9 % -6.19%
Operating Margin -111 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.5M shares +26.2%
Common Stock, Shares, Outstanding 32M shares +24.1%
Entity Public Float 120M USD +44.8%
Common Stock, Value, Issued 32K USD +24.1%
Weighted Average Number of Shares Outstanding, Basic 31.8M shares +25.7%
Weighted Average Number of Shares Outstanding, Diluted 31.8M shares +25.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 27.2M USD +1.38%
Research and Development Expense 43.6M USD +54.4%
General and Administrative Expense 13.6M USD +15.9%
Operating Income (Loss) -30M USD +1.55%
Nonoperating Income (Expense) 2.06M USD +64.6%
Net Income (Loss) Attributable to Parent -27.9M USD +4.38%
Earnings Per Share, Basic -0.89 USD/shares +23.9%
Earnings Per Share, Diluted -0.89 USD/shares +23.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.7M USD +8.65%
Marketable Securities, Current 18.8M USD -32.8%
Cash, Cash Equivalents, and Short-term Investments 29.5M USD -22%
Assets, Current 30.7M USD -21.2%
Property, Plant and Equipment, Net 5.62M USD +17.3%
Operating Lease, Right-of-Use Asset 1.67M USD -17.6%
Assets 38.3M USD -16.8%
Contract with Customer, Liability, Current 15.4M USD -47.5%
Liabilities, Current 22.4M USD -36.4%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 1.04M USD -31.2%
Liabilities 26.8M USD -38.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 155K USD -13.7%
Retained Earnings (Accumulated Deficit) -180M USD -18.4%
Stockholders' Equity Attributable to Parent 11.5M USD +321%
Liabilities and Equity 38.3M USD -16.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.27M USD -130%
Net Cash Provided by (Used in) Financing Activities 2.29M USD -41.2%
Net Cash Provided by (Used in) Investing Activities -9.5M USD -196%
Common Stock, Shares Authorized 100M shares +100%
Common Stock, Shares, Issued 32M shares +24.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.7M USD +8.65%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Operating Lease, Liability 1.84M USD -17.5%
Depreciation 1.27M USD +56.4%
Payments to Acquire Property, Plant, and Equipment 609K USD +75%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28M USD +3.78%
Lessee, Operating Lease, Liability, to be Paid 2M USD -17.7%
Property, Plant and Equipment, Gross 8.5M USD +32%
Operating Lease, Liability, Current 793K USD +12.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 635K USD -10.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 914K USD +19.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +37.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 160K USD -20.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 635K USD +15.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 546K USD -21.3%
Operating Lease, Payments 229K USD +15.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 331K USD +44%
Share-based Payment Arrangement, Expense 9M USD +48.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%